A new biotech called Five Discovery wants to give your brain the healing power of psychedelics without the hallucinations. They're not alone in the race, and the science behind it is surprisingly compelling.
Imagine a world where your doctor prescribes something inspired by one of the most powerful psychedelics on Earth. You take it, go about your day, and your brain quietly starts rewiring itself. No hallucinations. No six-hour supervised therapy sessions. No cosmic encounters with machine elves.
That's the bet a new biotech company called Five Discovery is making. And they're not alone.
The Problem With Tripping as Medicine
Psychedelics are having a moment. Psilocybin, MDMA, DMT: compounds once confined to counterculture are now front-page clinical trial material. Compass Pathways just hit its primary endpoint in a Phase 3 trial for psilocybin in treatment-resistant depression, with 39% of participants on the 25mg dose achieving a clinically meaningful MADRS reduction at week 6, and separate durability data from earlier trial responders showing benefits sustained over 26 weeks with just one or two doses. That's remarkable.
But there's a catch. A big one.
The hallucinogenic effects that make psychedelics famous also make them a nightmare for drug development. Patients on the drug can easily tell they're not on placebo, which makes blinding clinical trials incredibly difficult. Every dose requires a certified clinical setting, trained facilitators, and hours of supervised care. The FDA rejected Lykos Therapeutics' MDMA for PTSD in 2024, citing trial design flaws partly rooted in these exact challenges.
Scaling psychedelic therapy looks less like scaling a pill and more like scaling a spa. It's expensive, logistically brutal, and leaves most patients without access. So researchers started asking a radical question: what if you could keep the brain-healing benefits and ditch the trip entirely?
Enter the Neuroplastogen
The answer is a class of compounds called neuroplastogens: molecules that promote neuroplasticity (your brain's ability to form new connections and repair damaged circuits) without causing hallucinations.
Think of it like this. A psychedelic is a master key that opens two doors at once: one leading to neuroplasticity, and one leading to a hallucinogenic experience. Neuroplastogens are precision keys. They open only the door you actually want.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The science behind this is surprisingly elegant. Classical psychedelics like psilocybin and DMT work partly by activating the serotonin 5-HT2A receptor in your brain. Full activation of that receptor triggers both neuroplasticity and hallucinations. But researchers discovered that partial activation of the same receptor is enough to promote brain rewiring without the perceptual fireworks. The downstream signaling cascade (involving proteins called TrkB, mTOR, and AMPA receptors) still fires up, promoting new dendritic spine growth and synapse formation. The glutamate bursts and gene expression patterns associated with hallucinations simply don't occur.
In other words, the brain gets the renovation without the acid trip.
Five Discovery Joins the Race
Five Discovery launched publicly at the 6th Annual Psychedelic Therapeutics & Drug Development Conference in New Orleans on February 26-27, presenting its platform for the first time. The company develops small-molecule drugs inspired by 5-MeO-DMT, one of the most potent psychedelics known, often called "the God molecule" by enthusiasts.
Their approach strips away the hallucinogenic and focuses on what 5-MeO-DMT does at a cellular level: restoring dysfunctional neural circuits while reducing inflammation. The company emerged from the Kaivalya Ventures ecosystem and claims access to the largest real-world dataset of 5-MeO-DMT observations, which they're using to build a regulator-ready development roadmap.
Here's where it gets interesting. Five Discovery isn't going after depression or PTSD first, the obvious targets in psychedelic medicine. Their lead program targets Levodopa-Induced Dyskinesia (LID), a debilitating side effect of the standard Parkinson's disease treatment. Patients on levodopa for years often develop involuntary, uncontrollable movements. It's a smaller market, but that's strategic: LID could qualify for orphan drug designation, which comes with regulatory perks and a faster path to approval. From there, the company plans to expand into broader Parkinson's disease and other CNS disorders.
CEO Dr. Manesh Girn has described the company's mission as translating the plasticity benefits of serotonergic psychedelics into non-hallucinogenic medicines for circuit stabilization.
A Crowded Starting Line
Five Discovery is entering a field that's already buzzing with competition. Delix Therapeutics is arguably the most advanced player, with its compound DLX-159 (a next-generation neuroplastogen) in preclinical development. Their earlier compound, zalsupindole, is a non-hallucinogenic neuroplastogen that showed rapid structural brain changes comparable to or exceeding ketamine and psilocybin in preclinical studies, with no hallucinogenic effects in Phase 1.
Delix also collaborated on tabernanthalog (TBG), an ibogaine-inspired compound published in Nature in 2021, which promoted prefrontal cortex dendritic spine growth in rodents without the cardiac risks or hallucinations of the parent compound.
Then there's Clearmind Medicine, developing an intranasal formulation of MEAI for addiction and CNS disorders. Gilgamesh Pharmaceuticals has a partnership with AbbVie for next-generation psychiatric treatments. And academic labs, particularly David Olson's group at UC Davis, continue to churn out novel scaffolds and modified psychedelic analogs.
The conference itself drew over 200 attendees, including FDA and NIH experts, with more than 40 speakers covering everything from psilocybin for Parkinson's to clinical trial design for psychedelic-adjacent drugs.
The Big "If"
All of this sounds transformative, and it might be. But there's a critical caveat that hangs over the entire field: almost everything is still preclinical or very early clinical.
The evidence that non-hallucinogenic compounds retain meaningful therapeutic effects comes mostly from rodent models. Researchers measure success partly by the absence of something called the "head-twitch response" in mice (the animal equivalent of a hallucination signal). Whether that translates cleanly to human brains is still an open question.
Meanwhile, the hallucinogenic psychedelics are generating real clinical data. Compass Pathways is planning a rolling NDA submission for psilocybin between October and December 2026. If approved, it would be the first "classic" psychedelic to reach the market. Some researchers argue the trip itself might be therapeutically important; that the mystical experience contributes to lasting change in ways we don't fully understand.
Five Discovery and its competitors are essentially betting that's wrong. They're betting the brain chemistry is what matters, not the experience.
Why You Should Watch This Space
The neuroplastogen thesis is simple and compelling: if you can promote brain repair with a pill that patients take at home, you eliminate the entire supervised-therapy bottleneck. No certified clinics. No six-hour sessions. No DEA scheduling headaches (since these compounds aren't hallucinogenic, they could sidestep Schedule I restrictions entirely).
For a field where the leading MDMA therapy just got rejected and psilocybin's National Priority Voucher was blocked by HHS in October 2025, that regulatory simplicity is worth its weight in gold.
Five Discovery is early. Very early. They're a platform with a conference presentation, not a company with clinical data. But they're riding a scientific wave that has some of the smartest labs and biggest pharma players paying close attention. The question isn't whether non-hallucinogenic neuroplastogens will reach the clinic. It's whether they'll work as well without the trip as the originals do with it.
That answer could reshape psychiatry and neurology for a generation.
Deals & M&A4 min read
Gilead Just Paid $7.8B for a Protein the Size of a Paperclip
Gilead is spending $7.8 billion to acquire Arcellx and its next-gen CAR-T therapy for multiple myeloma. The secret weapon? A synthetic protein one-third the size of what competitors use, with clinical data that might just be best-in-class.
